Plain-English translation of NCT03218917 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested brensocatib, a new medication taken by mouth once daily, to see if it could help people with bronchiectasis (a lung disease where the airways become damaged and infected). Researchers studied whether the medication was safe and whether it reduced the number of serious lung infections people experienced. Participants received either the medication at one of two doses or a placebo (a pill with no active ingredient) for 24 weeks.
People with non-cystic fibrosis bronchiectasis suffer from repeated, serious lung infections that damage their airways over time. This trial was designed to find out whether this medication could reduce those infections and help patients stay healthier.
Participants took a pill by mouth once each morning before breakfast for 24 weeks straight. They were randomly assigned to receive either one of two doses of the medication or a placebo, and neither they nor the researchers knew which group they were in. During the trial, participants attended visits where doctors monitored their lung health, collected sputum samples, and tracked how many infections they developed.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States